VERNON, British Columbia, Feb. 09, 2018 (GLOBE NEWSWIRE) -- True Leaf Medicine International Ltd. (“True
Leaf” or the “Company”) (CSE:MJ) (FSE:TLA) (OTCQB:TRLFF), the quality of life cannabis company for people
and their pets, announces that the Company has granted stock options to directors, officers and consultants to purchase up to a
total 2,000,000 common shares, exercisable at a price of 94 cents per share, which is the closing price of the Company's shares on
February 6, 2018 which is the date of grant. The majority of the stock options are exercisable for five years until February 6,
2023. 100,000 of the stock option are exercisable for two years until February 6, 2020.
About True Leaf
Founded in 2013, True Leaf has two main operating divisions: True Leaf Medicine Inc. and True Leaf Pet Inc. The
Company’s goal is to provide federally-approved cannabis products that will be sold across Canada and the United States. True Leaf
Medicine Inc. was launched in July 2013 to become a licensed producer of medicinal cannabis for the Canadian market. True Leaf
Medicine Inc. has been granted approval by Health Canada to build its grow facility and will be subject to a Health Canada security
inspection upon completion to allow for the cultivation, manufacture, and distribution of cannabis products. Currently, True Leaf
does not have a license to produce cannabis.
Established in 2015, True Leaf Pet Inc. markets hemp-based products for the pet industry. The Company launched
the True Hemp™ pet supplement line in Canada, the United States, and Europe, becoming one of the first hemp-based pet product lines
to be marketed worldwide. True Hemp™ North American products are free of CBD and THC.
Risks of Investment in True Leaf
An investment in True Leaf has a high degree of risk including common to early stage companies such as small
equity market capitalization and public float, which may impair the liquidity of this investment. The Company can make no
assurances about the success of its products, or its licensing or marketing efforts; consequently investors in True Leaf may lose
some or all of their investments. True Leaf does not have a license to produce cannabis. Cannabis, marijuana, and any products
containing THC and CBD are illegal in the United States of America, notwithstanding laws of several states to the contrary.
Further, transportation of such products across state lines or across national boundaries remains a Federal Offense in the United
States of America, as well as the use of any federally chartered financial institution for transmittal or deposit of funds related
to the sale of such products. Accordingly, there can be no assurance that True Leaf will receive a license to produce cannabis from
Health Canada, and even if it were to receive such a license, there can be no assurance that it can import its products into the
United States for market or sale, or to repatriate the proceeds of such sales for the benefit of investors in this offering.
Forward-Looking Statements
This news release contains forward-looking statements; and management may make additional forward-looking
statements in response to your questions. Such written and oral disclosures are made pursuant to the Safe Harbor provision of the
Private Securities Litigation Reform Act of 1995. Although we believe our expectations expressed in such forward-looking statements
are reasonable, we cannot assure you that they will be realized. Investors are cautioned that such forward-looking statements
involve risks and uncertainties that could cause actual results to differ materially from the anticipated results, and therefore we
refer you to a more detailed discussion of the risks and uncertainties in the Company’s filings with the Securities and Exchange
Commission when available. The forward-looking statements contained in this news release are made only as of today; and True Leaf
Medicine International Ltd. is under no obligation to revise or update these forward-looking statements.
Media
Contact:
Paul
Sullivan
Director, Public Relations
Paul@trueleaf.com
O: 604-685-4742
M: 604-603-7358
Investor Contact:
Kevin Bottomley (Canada)
Director and Corporate Relations
Kevin@trueleaf.com
M: 778-389-9933
Tirth Patel (US)
Edison Advisors
tpatel@edisongroup.com
O: 646-653-7035
Follow True Leaf
trueleaf.com
twitter.com/trueleafpet
facebook.com/trueleafmedicine
instagram.com/trueleafpet
